Dyspnoea and antiplatelet agents: Revisited [1]

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1590-

  Husted, S ^a   Van Giezen, J J J ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; P2Y12 RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; TICLOPIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BRONCHOSPASM; CLINICAL TRIAL; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FLUID RETENTION; HEART FAILURE; HUMAN; IMMUNE RESPONSE; LETTER; MEDICAL RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VASCULAR DISEASE;

ADENOSINE; DYSPNEA; HUMANS; RECEPTORS, PURINERGIC P2;

EID: 34547777363     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01397.x     Document Type: Letter

References (4)

1. Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int J Clin Pract 2007 61 : 529 33.
2. Cannon CP, Husted S, Storey RF et al. The DISPERSE2 Trial: safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP antagonist, compared with clopidogrel in patients with non-ST segment elevation acute coronary syndromes. Poster Presented at American Heart Association Scientific Sessions; 13-6 November. Dallas, TX : American Heart Association, 2005, Tex. Presentation 2906.
3. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006 27 : 1038 47.
4. Husted S. Dyspnoea after AZD6140: safety first?: reply. Eur Heart J 2006 27 : 1505 6.